In 2004, it was reported that a chemical inhibitor of the kinase activity of EGFR was effective in a subset of lung cancer patients with activating somatic mutations of EGFR (Lynch et al., 2004; Paez et al., 2004). The gene discussed is EGFR; the disease is lung cancer.